Whitehawk Therapeutics Inc. (WHWK) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Whitehawk Therapeutics Inc. (NASDAQ: WHWK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $3.24 (-1.82% 1D, market cap $188.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, WHWK ranks #903 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), WHWK carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 89.4%, and ROIC of -35.0%. By comparison, ZNTL (Zentalis Pharmaceuticals Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $188.4M) and YARW (Yarrow Bioscience Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $186.1M). Among the 5-stock peer group, WHWK leads on earnings multiple (N/A) while SION leads on capital efficiency (-28.3% ROIC).
Per WHWK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001422142), Whitehawk Therapeutics Inc. generated $7.1M in revenue (-72.5% YoY), -$20.6M in net income, and -$98.0M in free cash flow against $150.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 36% of 52W Range • RSI-14 at 42.9 (NEUTRAL RANGE)
Altman Z-Score 3.11 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While WHWK currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.86) and Max Pain ($3.40) forces dealer call-delta covering toward $5.78.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Whitehawk Therapeutics Inc. (WHWK) slipped -1.82% to $3.24, trading at 36% of its 52-week range ($1.97 – $5.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
MarketBeat report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
Investing.com Canada report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on WHWK today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for WHWK. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Whitehawk Therapeutics Inc. (WHWK) ranks #903 by composite RQD confidence (28/100, grade E) and #586 by equity capitalization ($188.1M). Within this direct 5-issuer industry benchmark cohort, WHWK leads on earnings valuation at N/A trailing P/E, while SION leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. YARW currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with WHWK at 28/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| WHWK
ACTIVE
Whitehawk Therapeutics Inc. | E | 28/100 | — | 89.4% | -35.0% | -1.82% | $188.1M | Benchmark Subject |
| ZNTL Zentalis Pharmaceuticals Inc. | D- | 39/100 | — | — | -35.0% | -1.51% | $188.4M | /zntl-vs-whwk → |
| YARW Yarrow Bioscience Inc. | D- | 41/100 | — | — | -35.0% | -0.50% | $186.1M | /yarw-vs-whwk → |
| ADCT ADC Therapeutics SA | E | 33/100 | — | 92.9% | -35.0% | +2.69% | $190.2M | /adct-vs-whwk → |
| SION Sionna Therapeutics Inc. | D- | 38/100 | — | — | -28.3% | -3.25% | $180.8M | /sion-vs-whwk → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Whitehawk Therapeutics Inc. (WHWK) reported GAAP revenue of $7.1M (-72.5% vs. FY2024 revenue of $26.0M , and -70.7% cumulative change since FY2023) , GAAP net income of -$20.6M, operating cash flow of -$97.4M, and free cash flow of -$98.0M (-60.1% YoY). On the balance sheet, WHWK closed FY2025 with $150.8M in total assets against $0 in total debt (Altman Z-Score: 3.11, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $7.1M | -$20.6M | -$97.4M | -$98.0M | $150.8M | — |
| FY2024 (FY) | 2024-12-31 | $26.0M | -$63.7M | -$59.5M | -$61.2M | $70.3M | — |
| FY2023 (FY) | 2023-12-31 | $24.4M | -$65.8M | -$59.7M | -$59.7M | — | — |
As of 2026-11-02, Whitehawk Therapeutics Inc. (NASDAQ: WHWK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $3.24 (-1.82% 1D, market cap $188.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, WHWK ranks #903 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), WHWK carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 89.4%, and ROIC of -35.0%. By comparison, ZNTL (Zentalis Pharmaceuticals Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $188.4M) and YARW (Yarrow Bioscience Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $186.1M). Among the 5-stock peer group, WHWK leads on earnings multiple (N/A) while SION leads on capital efficiency (-28.3% ROIC).
Per WHWK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001422142), Whitehawk Therapeutics Inc. generated $7.1M in revenue (-72.5% YoY), -$20.6M in net income, and -$98.0M in free cash flow against $150.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
WHWK last traded at $3.24 (-1.82% on volume of 153,351 shares), positioning the stock -16.06% below its 50-day simple moving average ($3.86) and -15.62% below its 200-day simple moving average ($3.84). Across its 52-week range of $1.97 to $5.50, WHWK sits at the 36.0% percentile with a 14-day RSI of 42.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.83 to $3.65).
Why WHWK Stock slipped -1.82% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, WHWK scores 28 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:
Taken together, the rating frames WHWK as a stock where the cash-generation and insider-conviction pillars are the largest drags. The upside case rests on a turnaround in operating economics, which the source data does not show yet. The valuation tradeoff is that a $188.1M market cap is being carried against negative operating margins, so price is not supported by current cash earnings. This is an analytical read of the rating's components, not personalized advice.
Whitehawk Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry, per the company profile. Per the SEC financials, FY 2025 revenue was $7.1M, down from $26.0M in FY 2024. The source data does not describe specific products, customers, or the monetization model beyond this sector classification.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $7.1M | $-114.4M | $-20.6M | N/A | $-98.0M | $37.6M | N/A |
| FY 2024 | $26.0M | $-67.5M | $-63.7M | N/A | $-61.2M | $28.7M | N/A |
| FY 2023 | $24.4M | $-71.9M | $-65.8M | N/A | $-59.7M | N/A | N/A |
Per the market data, gross margin is 89.4% while operating and net margins are both -60%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 3.11 and the Piotroski F-Score is 3/9, with Debt/Equity of 0.5. Per the SEC financials, free cash flow was negative in every reported period, and cash declined from $37.6M at FY 2025 relative to the FY 2024 reading of $28.7M, which rose. The profitability picture is loss-making throughout the reported window.
Per the recent news wire, the items are headline-level only. A MarketBeat item reports a consensus target price of $8.33 according to brokerages, flagged YELLOW. A Form 4 filing by director and CEO David James Lennon is noted, flagged YELLOW. A MarketBeat item reports the stock fell 4.6%, flagged RED under RISK WATCH. Other items are Yahoo! Finance Canada seasonal chart pages on Fennec Pharmaceuticals and Surrozen, plus a TradingKey dividend-screen article, all flagged YELLOW. Per the Butterfly Supply-Chain Graph, there are no proprietary signals and no supply-chain links recorded.
Per the Butterfly Supply-Chain Graph, supply_chain is NONE and butterfly_links is empty. The source data contains no upstream or downstream dependencies, sector correlation mapping, or bottleneck analysis. A prospective investor should note that the graph cannot identify second-order ripples from this data alone.
Real-time company headlines, analyst actions, and sector developments for Whitehawk Therapeutics Inc. (WHWK) • Click "Debate This Headline" to argue it in the Roar Pit below
MarketBeat report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
Investing.com Canada report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.
Welcome to the WHWK (Whitehawk Therapeutics Inc.) Roar Pit. Current RQD Composite is 28/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on WHWK, but look at what you are paying: current EV/EBITDA multiples with 89.4% gross margins. Unless Whitehawk Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on WHWK, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.24 (52-wk range $1.97 - $5.50), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).